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ARTICLE
Copy number variation of scavenger-receptor cysteine-
rich domains within DMBT1 and Crohn’s disease
Shamik Polley1, Natalie Prescott2, Elaine Nimmo3, Colin Veal1, Ida Vind4, Pia Munkholm4, Peder Fode4,
John Mansﬁeld5, Paal Skyt Andersen4, Jack Satsangi3, Christopher G Mathew2,6 and Edward J Hollox*,1
Previous work has shown that the gene DMBT1, which encodes a large secreted epithelial glycoprotein known as salivary
agglutinin, gp340, hensin or muclin, is an innate immune defence protein that binds bacteria. A deletion variant of DMBT1 has
been previously associated with Crohn’s disease, and a DMBT1− /− knockout mouse has increased levels of colitis induced by
dextran sulphate. DMBT1 has a complex copy number variable structure, with two, independent, rapidly mutating copy number
variable regions, called CNV1 and CNV2. Because the copy number variable regions are predicted to affect the number of
bacteria-binding domains, different alleles may alter host–microbe interactions in the gut. Our aim was to investigate the role
of this complex variation in susceptibility to Crohn’s disease by assessing the previously reported association. We analysed the
association of both copy number variable regions with presence of Crohn’s disease, and its severity, on three case–control
cohorts. We also reanalysed array comparative genomic hybridisation data (aCGH) from a large case–control cohort study for both
copy number variable regions. We found no association with a linear increase in copy number, nor when the CNV1 is regarded as
presence or absence of a deletion allele. Taken together, we show that the DMBT1 CNV does not affect susceptibility to Crohn’s
disease, at least in Northern Europeans.
European Journal of Human Genetics advance online publication, 27 January 2016; doi:10.1038/ejhg.2015.280
INTRODUCTION
Crohn’s disease (CD) is a chronic debilitating inﬂammatory disease
that most frequently affects the terminal ileum but can affect any part
of the gastrointestinal tract. In the West, CD has a prevalence of ~ 150
per 100 000,1 with environmental and genetic variations making an
approximately equal contribution to disease risk.2
The most recent progress in elucidating the genetic variation
responsible for CD has come from SNP-based genome-wide associa-
tion studies, which have identiﬁed 163 loci that contribute to the
genetic risk of the disease.3,4 Nevertheless, even with well-powered
analyses of 15 000 cases and 15 000 controls, only 13.6% of disease
variance has been explained, suggesting that other genetic risk variants
exist that are not interrogated by current SNP-GWAS approaches.
Copy number variation, where a whole or part of a gene differs in
copy number in different individuals, is a potential candidate type of
variation that is often not well-tagged by ﬂanking SNP alleles.5 CNV of
the beta-defensin genes and amylase has been shown to affect
susceptibility to psoriasis and obesity, respectively,6,7 indicating that
CNV can contribute to genetic variance of common complex diseases.
A genome-wide association study directly interrogating CNV by
arrayCGH identiﬁed a CNV in the HLA region and at the IRGM
gene associated with CD,8 but other more complex CNVs may also be
associated with CD.
Because methods to reliably and cost-effectively type CNV genome-
wide are lacking, recent literature has focused primarily on studies of
candidate genes chosen for their known role in the aetiology of CD.
One example is association of CNV of the beta-defensin gene region
with CD, where an initial study supported an association of low
beta-defensin copy number with CD, an effect only seen in colonic CD
rather than ileal CD.9 A subsequent study on a larger cohort of cases
and controls found a signiﬁcant association but in the reverse
direction,10 and both studies are limited by low statistical power and
limitations in the technology used to type CNV.11,12 Indeed, the large
genome-wide arrayCGH association study of CD patients and controls
found no evidence of association with beta-defensin CNV,8 a ﬁnding
supported by a rigorous study, which also showed that real-time
quantitative PCR methods often used to type CNV could easily
generate false-positive associations of CNV and disease.11 This
emphasised the importance of robust copy number detection methods
that minimised the chance of false-positive results.
Another CNV that has been associated with CD is a deletion of
part of the DMBT1 gene, called DMBT1SR47− .13 CD patients have
been shown to have a higher frequency of this deletion compared to
controls. DMBT1 is a particularly attractive candidate gene, as it
encodes a large secreted glycoprotein (also known as salivary
agglutinin, gp340, hensin or muclin) that is expressed in the
gastrointestinal tract and is upregulated in CD.14 Furthermore,
DMBT1 binds a wide variety of Gram positive and Gram negative
bacteria, at least in saliva and the lung,15,16 and DMBT1 knockout
mice show subtly enhanced sensitivity to experimentally induced
colitis,13 although this has not been conﬁrmed with an alternative
DMBT1 knockout mouse.17 Nevertheless, the evidence suggests that
DMBT1 has an important innate defence function in the
gastrointestinal tract.
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The canonical DMBT1 protein is composed of a regular array of 13
scavenger-receptor cysteine-rich (SRCR) domains interspersed with
SID domains, and followed by a CUB domain, a diverged SRCR
domain, a further CUB domain and then ﬁnally a zona pellucida
domain.18 The polymorphic DMBT1SR47− deletion previously asso-
ciated with CD leads to the loss of four SRCR domains (SRCR3-
6),19,20 Figure 1, and since these SRCR domains have been shown to
contain the binding sites for bacteria,15 it has been suggested that the
deletion leads to a quantitative change in the ability of DMBT1 to bind
bacteria, limiting the protection of the host mucosa against intestinal
ﬂora and therefore contributing to the pathogenesis of CD.13
Recent work has demonstrated that the DMBT1SR47− polymorphic
deletion is in fact part of a wide spectrum of alleles affecting the copy
number of SRCR domains within DMBT120 (Figure 1). Speciﬁcally, at
the locus where the polymorphic deletion occurs (termed CNV1),
there is also a polymorphic duplication allele of the same 4-SRCR
domain repeat unit. Furthermore, at the C-terminal SRCR region
there is a further CNV (termed CNV2) where a single SRCR domain
unit can vary between 0 and 11 copies per diploid genome. Taken
together, this indicates that although the canonical DMBT1 13-SRCR
array structure represents a common genotype containing 26 tandemly
arrayed SRCR domains per diploid genome (2 × 13-SRCR arrays), in
reality a wide range of SRCR domain numbers have been observed
within DMBT1 ranging from 14 to 40 SRCR domains per diploid
genome. Therefore, through allelic variation alone, DMBT1 molecules
have the potential to contain between 7 and 20 SRCR domains, as a
conservative estimate.20
Given this extensive variation, and the robust methods used to
type it on small amounts of genomic DNA, we endeavoured to ﬁrst
replicate the original observation of an association of SRCR copy
number on CD on three large Northern European case–control
cohorts, and to extend the analysis to the full allelic spectrum of
DMBT1 SRCR domain variation, which might explain a signiﬁcant
amount of the genetic variance in CD susceptibility.
METHODS
Danish cohort
DNA was extracted from the peripheral blood of native Danish CD patients
recruited from a well-deﬁned geographical region (Copenhagen capital area,
Denmark) during a 2-year period from 1 January 2003 to 31 December 2004.
The details of the Danish CD cohort are described elsewhere.21,22 DNAs from
healthy blood donors from the Danish national blood bank were included as
controls.
Scottish cohort
DNA was isolated from the peripheral blood from CD patients were collected at
the Western General Hospital, Edinburgh, Scotland, which is a tertiary referral
centre for inﬂammatory bowel disease (IBD) in South-East Scotland. Detailed
description of the Scottish cohort is given elsewhere.11 Written consent from
Figure 1 Overview of the copy number variation at DMBT1. A dotplot shows the repeated nature of the DMBT1 gene (shown from a screenshot from the
UCSC genome browser). The tandemly arranged SRCR repeat regions are shown, including SRCR14, which does not bind bacteria. The genome assembly
shows one assembled copy of CNV1 and four assembled copies of CNV2. CNV regions, as recorded in the Database of Genome Variants, are shown below
the DMBT1 gene structure. Below these, location of reference and test amplicons of the four independent paralogue ratio tests (PRTs) that measure copy
number of CNV1 and CNV2 are shown.
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CD patients was obtained prior to inclusion in the study. DNA from blood
samples from unrelated spouses/friends of IBD patients or samples obtained
from the Scottish Blood Transfusion Service were used as healthy controls. The
study protocol was approved by the Medicine and Oncology Subcommittee of
the Lothian Local Research Ethics Committee (LREC 2000/4/192).
English cohort
White European patients with CD were recruited from specialist IBD clinics in
London and Newcastle as reported elsewhere23 after informed consent and
ethical review (REC 05/Q0502/127). Patients were recruited from Guy’s and St
Thomas’ Hospitals London, United Kingdom, St Mark’s Hospital London,
United Kingdom, and the Royal Victoria Inﬁrmary, Newcastle, United King-
dom after ethical review and informed consent from CD patients. Human
random control (HRC) DNA samples from lymphoblastoid cell lines derived
from UK individuals (from the ECACC collection held by Public Health
England: http://www.phe-culturecollections.org.uk/) were used as control
samples.
Copy number typing
We used our extensively validated and robust paralogue ratio test approach to
type copy number on genomic DNA samples, as described previously.20,24
Brieﬂy, test and reference amplicons are generated using the same PCR primer
pair, one primer ﬂuorescently labelled. The primers are designed so that test
and reference amplicons can be distinguished by a small difference in product
length by capillary electrophoresis on an ABI 3100xl (Applied Biosystems/
Life Technologies, Paisley, UK). Eight positive control DNAs from the HapMap
panels were run on every plate to act as calibrators (Supplementary Table 1).
Our previous study, using repeat testing of identical samples, estimates the
experimental error rate of CNV1 determination to be 0.37% and of CNV2 to
be 0.33%.20 WTCCC data was provided courtesy of the WTCCC Access
Committee and Dr Matthew Hurles (Wellcome Trust Sanger Institute). All data
have been deposited with dbVar http://www.ncbi.nlm.nih.gov/dbvar accession
number nstd77.
Statistical analysis
Raw copy number data from PRT was normalised to have a SD of one across
the cohort. Data from cases and controls were analysed together, and, following
visual inspection of a histogram of the raw data, a Gaussian mixture model
(GMM) ﬁtted to the data with the number of components (individual Gaussian
distributions corresponding to each copy number) of the model determined by
inspecting the number of peaks in the histogram, and by previous knowledge of
the range of copy number variation in cohorts described previously. The
variance of each Gaussian distribution was assumed to be the same when ﬁtting
the models to the data. Fitting the GMM allows integer copy numbers to be
called from the data with an associated Bayesian posterior probability value for
each call. It also allows ﬁtting of two different models for cases and controls to
provide a formal test of association of copy number with disease.25 This analysis
is implemented in the R package CNVtools v 1.42.3 (www.bioconductor.org).
Examples of GMM ﬁts to the data are shown in Supplementary Figure 1, for
PRT data.
The raw aCGH data for the CD cohort was normalised two different ways:
named as normalised1 and normalised2. In case of ﬁrst normalisation
(normalised1), the log of the ratio of the red and green channel data (log(R/
G)) was used whereas in second normalisation (normalised2), the log of the
ratio of the quantile-normalised red and green channel data (log(QNorm(R)/
QNorm(G))) was calculated. Data from 12 probes spanning CNV1 and 18
probes spanning CNV2 were summarised using the ﬁrst principal component
of the data, so that each sample had one summary value for CNV1 and one
summary value for CNV2. For CNV1, plotting the data on a histogram gave
three clusters, and CNV1 copy number was called using a three-component
GMM. For some samples, duplicate aCGH data were available. In such cases,
the duplicate sample with the lowest posterior probability in support of an
integer copy number was removed prior to case–control analysis. Normalised1
data were used for CNV1 case–control analysis, and normalised2 data were
used for CNV2 analysis. Examples of GMM ﬁts to the data are shown in
Supplementary Figure 2, for aCGH data.
Fisher’s exact tests and regression analyses were performed using R 3.1.0
(https://www.r-project.org/), and meta-analysis used the R package meta v4.3.
All cohorts had a power of40.9 to detect the effect size previously observed13
at a signiﬁcance level of 0.05 or below, with the exception of the Danish cohort,
which had a power of 0.76.
RESULTS
We genotyped 1449 cases and 994 controls from the English, Scottish
and Danish cohorts using our paralogue ratio test approach, described
previously. The copy number distribution of CNV1 ranged from 0 to
4 in all populations, and CNV2 ranged from 1 to 11 (Supplementary
Figures 1 and 2), which is consistent with previous studies
on European populations.20 Histograms of the raw data show clear
Figure 2 Analysis of calling CNV1 copy number using PRT and arrayCGH.
(a) Six hundred and eighty eight samples from the English CD cohort and 97
samples from the Scottish CD cohort with copy number measured by both
PRT (y axis) and aCGH (x axis). aCGH data here are normalised using log(R/
G) and represent the ﬁrst principal component value of 12 probes. (b) As
above but with aCGH, data here are normalised using log(QNorm(R)/QNorm
(G)), where Qnorm is quantile-normalised.
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clustering for CNV1 but poorer clustering for CNV2, where clear
histogram peaks are seen only for lower copy numbers. Furthermore,
visual inspection shows that for CNV2 calling quality varied from
cohort to cohort, and this is reﬂected in the quality score of the GMM
(Q; Supplementary Table 2) that is ﬁtted to the data and used to call
integer copy numbers. Because of this, we used two approaches for
testing for association with disease. First, we called integer copy
number using CNVtools and used those copy numbers in a standard
Fisher’s exact test. Second, we used a feature of CNVtools that tests for
association at the same time as ﬁtting the GMM, which has the
advantage of explicitly taking into account uncertainty in copy number
calling.
A subset of both the English and Scottish cohorts had been analysed
by arrayCGH as part of the Wellcome Trust Case Control Consortium
genome-wide CNV analysis. This allowed us to compare our copy
number calling using PRT with DNA dosage data generated by
arrayCGH. The arrayCGH data and PRT raw data were correlated for
both CNV1 (r2= 0.75 using normalised1 data; r2= 0.65 using normal-
ised2 data) and for CNV2 (r2= 0.55 using normalised1 data; r2= 0.43
using nomalised2 data). Figure 2 shows that summarising the aCGH
data as the ﬁrst principal component of 12 probes spanning CNV1 gives
concordance with PRT results, and suggests that these aCGH data could
call CNV1 copy number quite robustly. Compared to the normalised2
approach (Figure 2b; see Methods), data normalised using the normal-
ised1 approach showed a stronger correlation with the PRT raw data
and showed better distinction between the two main peaks (copy
numbers 1 and 2; Figure 2a). Therefore, the normalised1 data were
chosen for the full cohort analysis. For CNV2, although aCGH
measures the DNA dosage and is correlated with PRT calls, there is a
single continuous distribution with no evidence of clustering about
integer copy numbers (Figure 3), and the correlation with PRT raw data
is much weaker than in the case with the CNV1 data.
For the ﬁrst test of association of copy number with CD, we
followed the approach described in Renner et al. In that paper CNV1
was genotyped as the deletion DMBT1SR47− using a PCR-based
approach. Previously, we have shown that this is a simpliﬁcation of
the CNV, with duplications also being observed in the population.20
Copy number 0 is equivalent to a homozygous deletion DMBT1SR47− /− ,
1 to a heterozygous deletion DMBT1SR47+/−and 2 to a homozygous
reference DMBT1SR47+/+. Copy numbers 3 and 4 represent heterozygous
and homozygous duplications, respectively. To directly compare our data
with the previously published data, we called deletion genotype from our
CNV1 data, grouping all CNV1 copy numbers of 2 and above as
homozygous reference genotype. We also called deletion genotype from
the WTCCC aCGH data from samples not included in our English and
Scottish cohorts. For the 785 samples where we had matching PRT and
arrayCGH data, six samples disagreed for the genotype called, giving a
discordance rate of o1.6% (upper 95% conﬁdence limit). All 785
samples with matching PRT data were removed from the WTCCC
cohort analysis. Analysis of allele frequency counts in each cohort showed
a higher frequency of the deletion allele in CD patients in three of the
four cohorts, but the differences were not statistically signiﬁcant (Mantel-
Haenszel OR 1.10, 95% CI 0.97–1.24, P=0.40; Table 1; Figure 4a).
We then asked whether full copy number typing of CNV1, where
higher copy numbers corresponding to duplications can be called,
would strengthen our association. Unfortunately, aCGH did not call
high copy numbers effectively (Figure 2; Supplementary Figure 2), and
so we were limited to the cohorts typed by PRT. By using logistic
regression to test the linear effect on CD case–control status with each
increase in copy number, we found no signiﬁcant effect (combined
P= 0.17; Table 2; Figure 4b), a result conﬁrmed when analysed using
the likelihood approach of CNVtools (Supplementary Table 2). This
suggests that the duplication allele at CNV1 is unlikely to protect
against CD, although given the low frequency of this allele we may not
have power to detect anything but a strong effect.
We then examined whether copy number at CNV2 was associated
with CD. Analysis of our three cohorts provided apparently contra-
dictory results, with the Scottish cohort showing no association, the
English cohort showing a marginally higher copy number (P= 0.01) in
the CD patients and the Danish cohort showing a marginally lower
(P= 0.03) copy number in the CD patients (Table 3; Supplementary
Table 3). This variation is due to variation in the patients rather than
the controls, as the mean copy number in the controls is remarkably
Figure 3 Analysis of calling CNV2 copy number using PRT and arrayCGH.
(a) Six hundred and eighty eight samples from the English CD cohort and 97
samples from the Scottish CD cohort with copy number measured by both
PRT (y axis) and aCGH (x axis). aCGH data here are normalised using log(R/
G) and represent the ﬁrst principal component value of 18 probes. (b) As
above but with aCGH, data here are normalised using log(QNorm(R)/QNorm
(G)), where Qnorm is quantile-normalised.
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consistent across all three cohorts (Table 3). The simplest interpreta-
tion of the results is that of stochastic variation about a null result, and
indeed combining the data sets suggest the following: combined
P= 0.446, Mantel-Haenszel OR= 0.98, 95% CI 0.927–1.034
(Figure 4c). It may be the case that batch effects in typing high copy
numbers of this CNV have generated this inconsistency. Indeed, even
carefully designed CNV studies are prone to batch effects and the
Scottish cohort was the only cohort where cases and controls
originated from the same laboratory, and were randomly distributed
across all experimental plates.
For the Scottish cohort, age of CD ﬁrst diagnosis data were available
as a proxy for age of onset, and it is conceivable that CNV of the SRCR
domains within DMBT1 could affect this trait, notwithstanding an
overall effect on risk of developing CD. We analysed the effect of copy
number at both CNV1 and CNV2 with age at diagnosis (Table 4),
controlling for the known effect of sex on age of onset. We conﬁrmed
that females have on average a later age of onset in this cohort,
but found no evidence of an effect of CNV1 or CNV2. Analysis of
CNV1 coded as DMBT1SR47 genotype also showed no signiﬁcant effect
on age at diagnosis.
DISCUSSION
Previous work has shown the importance of DMBT1 in the aetiology
of CD using studies of knockout mice and genetic association of the
DMBT1SR47− deletion allele within the gene and CD. However, the
genetic association had not been tested on another case–control cohort
and had a relatively small sample size, and such association studies
are prone to false-positive results through differential bias or chance
effects. Furthermore, the effect size observed (OR= 1.75) is larger than
most effect sizes identiﬁed by GWAS26 and, if correct, could
potentially be of clinical importance.
Table 1 Association analysis of DMBT1SR47 genotype with Crohn’s disease
Population Cohort
DMBT1SR47− /−
number (frequency)
DMBT1SR47+/−
number (frequency)
DMBT1SR47+/+
number (frequency) Total
Fisher’s exact
test P-value Odds ratio
Scottish CD 5 (0.01) 57 (0.16) 286 (0.82) 348 0.93 0.97 (0.68–1.39)
Controls 3 (0.01) 61 (0.18) 276 (0.81) 340
English CD 7 (0.01) 178 (0.19) 761 (0.80) 946 0.20 1.19 (0.91–1.56)
Controls 2 (0.00) 79 (0.16) 399 (0.83) 480
Danish CD 5 (0.03) 34 (0.22) 116 (0.75) 155 0.09 1.53 (0.95–2.46)
Controls 4 (0.02) 26 (0.15) 144 (0.83) 174
WTCCC CD 16 (0.01) 226 (0.18) 988 (0.80) 1230 0.76 1.05 (0.90–1.23)
Controls 41 (0.01) 535 (0.17) 2517 (0.81) 3093
Total CD 33 (0.01) 495 (0.19) 2151 (0.80) 2679 0.22 1.07 (0.96–1.21)
Controls 50 (0.01) 701 (0.17) 3337 (0.82) 4087
Figure 4 Meta-analysis of cohorts in the association study. Forest plots of odds ratios for the deletion variant of DMBT1SR47 for Scottish, English, Danish and
WTCCC data sets only (a), Forest plots of the odds ratio per copy for CNV1 (b) and CNV2 (c). Each diagram displays the odds ratios for each data set as a
box with the 95% conﬁdence interval marked by lines. The ‘MH Summary’ represents the 95% conﬁdence interval of the Mantel-Haenszel combined odds
ratio for all data sets, whereas ‘Combined’ represents the 95% conﬁdence interval for totals for CNV1 and CNV2.
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We conducted this study to try and replicate a previous genetic
association study of the DMBT1SR47− deletion with CD. We used a
combination of publicly available data, generated as part of the
Wellcome Trust Case Control Consortium study of copy number
variation, and data were generated on three case–control cohorts using
paralogue ratio tests to type the DMBT1SR47− deletion on a total of
2679 cases and 4088 controls. Comparisons between PRT raw data
and arrayCGH data showed that while arrayCGH reﬂects copy
number variation, correct normalisation is important to optimise
the copy number calling, even when clear clusters of raw values are
observed. After meta-analysis of our data, we did not replicate the
original association,13 and this could be due to a number of reasons.
It is possible that, because we focused on Northern European
populations and the original study was conducted on an Italian
sample, the DMBT1SR47− deletion allele confers susceptibility to CD
only in Italian populations, perhaps due to an interaction with diet. It
is also possible that different diagnosis criteria were used, perhaps
enriching for a particularly severe clinical phenotype in the original
study, although there is no indication of this in the original study.
However, the most likely explanation is that this was a false-positive
result. It should be noted that in the original study, the genotype
frequencies for the cases show an extreme deviation from Hardy-
Weinberg Equilibrium, with an excess of heterozygotes (P= 5× 10− 4,
χ2 test with 1 d.f.), which we do not observe in our data. We
conducted a test for heterogeneity across our data sets and including
the original data previously published, which suggested that the
original data set was from a distinct population (P= 0.039) and
combining all the data in a meta-analysis would be inappropriate.
Previous analysis of CNVs within the DMBT1 gene has shown that
the DMBT1SR47− deletion is in fact part of a multiallelic CNV called
CNV1, and that another CNV, called CNV2, is 3′ to CNV1 and also
affects the number of SRCR domains.20 By using our PRT assays, we
typed multiallelic copy number for both CNV1 and CNV2 on
the Scottish, English and Danish case–control cohorts, and found no
evidence of association. In this study, we use our copy number typing
approaches to call the full spectrum of copy number variation at both
CNV1 and CNV2. Given that the full range of copy numbers can be
typed, we might expect more power to detect any association that was
linearly dependent on copy number, but we do not detect such an
effect for CNV1 nor CNV2, nor could we show any association with
CNV1 copy number or CNV2 copy number.
One important feature of the DMBT1SR47− deletion allele is that, as
part of CNV1, it has a remarkably high mutation rate of 0.7–2.7% per
generation.20 This has the consequence that DMBT1SR47− deletions
will be generated by recurrent mutation, thereby eroding linkage
disequilibrium with neighbouring SNP alleles. A recent study has
identiﬁed a SNP allele associated with CD within DMBT1 at genome-
wide signiﬁcance levels.27 It is unclear why this allele has not been
identiﬁed by GWAS studies, and indeed it may not be in LD with
SNPs assayed by GWAS studies; so further research is needed to
dissect the nature of this association. Our results in this study do not
exclude an association of single nucleotide variation within DMBT1
and CD, nor do they exclude a role for DMBT1 in CD, which has
previously been suggested by the Dmbt1 knockout mouse. Indeed,
DMBT1 shows increased expression in the intestinal mucosa in CD
patients, and this increased expression is dependent on NOD2
activation, because this response is abolished in CD patients homo-
zygous for a NOD2 SNP allele causing a NOD2 frameshift, an allele
also associated with CD.28 Given the role of DMBT1 in binding
bacteria,29,30 it seems reasonable to assume that the DMBT1SR47−
deletion allele encodes a protein that has an altered interaction
with the intestinal ﬂora, and mediates its effect via its interactions
with bacteria. However, our study has excluded a role for the extensive
copy number variation of DMBT1 in strongly modifying the
susceptibility to CD.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
Table 2 Association analysis of DMBT1 CNV1 copy number with
Crohn’s disease
Scottish English Danish
CNV1 copy
number CD Controls CD Controls CD Controls
0 5 3 7 2 5 4
1 57 61 178 79 34 26
2 275 263 731 387 114 139
3 11 12 30 11 2 5
4 0 1 0 1 0 0
n 348 340 946 480 155 174
Failed 2 0 3 0 1 5
Mean 1.84 1.84 1.83 1.85 1.73 1.83
SD 0.48 0.49 0.47 0.44 0.54 0.49
OR (95% CI) per copy 0.979
(0.717–1.335)
0.886
(0.694–1.126)
0.673
(0.435–1.028)
P (log reg) 0.891 0.323 0.070
Table 3 Association analysis of DMBT1 CNV2 copy number with
Crohn’s disease
Scottish English Danish
CNV2 copy
number CD Controls CD Controls CD Controls
1 0 0 1 0 0 0
2 13 8 14 11 2 9
3 29 34 98 48 12 21
4 82 79 229 110 30 44
5 78 83 319 125 46 43
6 70 69 164 104 36 33
7 37 26 67 51 16 11
8 23 18 35 23 10 11
9 11 10 3 4 4 5
10 2 1 2 4 0 0
11 1 0 0 0 0 0
n 346 328 932 480 156 177
Failed 4 12 17 0 0 2
Mean 5.27 5.15 4.95 5.15 5.34 4.97
SD 1.68 1.56 1.31 1.49 1.46 1.63
OR 1.05 (0.95–1.15) 0.901 (0.832–0.976) 1.169 (1.017–1.348)
P 0.329 0.0103 0.0297
Table 4 Multiple linear regression analysis testing association of CNV
with age of onset
Variable B B (SE) t-Statistic P
Intercept 30.4 7.31 4.15 4.3×10−5
Sex (reference= female) −4.76 1.83 −2.61 0.0097
CNV1 0.804 1.62 0.43 0.67
CNV2 0.0113 0.513 0.022 0.98
N=306, 7 omitted due to missing data.
Predictor variables were sex, CNV1 copy number and CNV2 copy number, with age at diagnosis
the dependent variable. The values for the effect size (B) with its SE are given, together with
the corresponding t-statistic used to test whether the value of B is signiﬁcantly different from
zero. The P-value of that test is given in the rightmost column.
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